- Analyst H.C. Wainwright set an $8.00 price target for Can-Fite BioPharma (AMEX: CANF), indicating a potential 72.80% upside.
- Can-Fite BioPharma’s Namodenoson drug achieved its primary safety goal in a Phase 2a pancreatic cancer study.
- The company secured a valuable patent in Japan for Namodenoson’s anti-obesity technology, contributing to a 55.89% surge in its stock price.
On July 2, 2026, analyst firm H.C. Wainwright set a price target of $8.00 for Can-Fite BioPharma. Can-Fite BioPharma is a clinical-stage biotechnology company, which means it focuses on developing and testing new drugs that are not yet available for public sale. The company develops small molecule drugs to treat cancer and inflammatory diseases, positioning itself as a key player in the biotechnology sector.
When the target was set, Can-Fite BioPharma’s stock price was $4.63. This new price target suggests a potential increase of about 72.80% from its price at the time. Such targets are often influenced by a company’s recent performance and future prospects, including progress in its drug development pipeline and overall stock market analysis.
Recent developments support this positive outlook. As highlighted by GlobeNewswire, Can-Fite BioPharma announced its Phase 2a study for the drug Namodenoson in pancreatic cancer patients achieved its main safety goal. The drug was well-tolerated, and one patient who received it as a second-line treatment has survived for more than 18 months, showcasing promising clinical trial results for this potential pancreatic cancer treatment.
Further strengthening its position, the company also secured a patent in Japan for Namodenoson’s anti-obesity technology, as reported by GlobeNewswire. This patent protects the company’s intellectual property, which are the legal rights to its invention, in one of the world’s largest pharmaceutical markets, enhancing Can-Fite BioPharma’s competitive edge.
The market has reacted positively to this news. Shares of Can-Fite BioPharma surged by 55.89%, an increase of $1.66 per share, to its current price of $4.63. Trading volume is very high at over 57.03 million shares, showing significant investor interest. The company currently has a market capitalization of approximately $2.49 million, reflecting its valuation in the stock market.
